Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

241 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Epigenetic Control of Redox Pathways in Cancer Progression.
Shah V, Lam HY, Leong CH, Sakaizawa R, Shah JS, Kumar AP. Shah V, et al. Among authors: lam hy. Antioxid Redox Signal. 2025 Jan 16. doi: 10.1089/ars.2023.0465. Online ahead of print. Antioxid Redox Signal. 2025. PMID: 39815993 Review.
Mast cells: Therapeutic targets for COVID-19 and beyond.
Lam HY, Tergaonkar V, Kumar AP, Ahn KS. Lam HY, et al. IUBMB Life. 2021 Nov;73(11):1278-1292. doi: 10.1002/iub.2552. Epub 2021 Sep 21. IUBMB Life. 2021. PMID: 34467628 Free PMC article. Review.
Delineating the role of nuclear receptors in colorectal cancer, a focused review.
Manickasamy MK, Jayaprakash S, Girisa S, Kumar A, Lam HY, Okina E, Eng H, Alqahtani MS, Abbas M, Sethi G, Kumar AP, Kunnumakkara AB. Manickasamy MK, et al. Among authors: lam hy. Discov Oncol. 2024 Feb 19;15(1):41. doi: 10.1007/s12672-023-00808-x. Discov Oncol. 2024. PMID: 38372868 Free PMC article. Review.
Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.
Glaviano A, Lau HS, Carter LM, Lee EHC, Lam HY, Okina E, Tan DJJ, Tan W, Ang HL, Carbone D, Yee MY, Shanmugam MK, Huang XZ, Sethi G, Tan TZ, Lim LHK, Huang RY, Ungefroren H, Giovannetti E, Tang DG, Bruno TC, Luo P, Andersen MH, Qian BZ, Ishihara J, Radisky DC, Elias S, Yadav S, Kim M, Robert C, Diana P, Schalper KA, Shi T, Merghoub T, Krebs S, Kusumbe AP, Davids MS, Brown JR, Kumar AP. Glaviano A, et al. Among authors: lam hy. J Hematol Oncol. 2025 Jan 13;18(1):6. doi: 10.1186/s13045-024-01634-6. J Hematol Oncol. 2025. PMID: 39806516 Free PMC article. Review.
Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment.
Glaviano A, Wander SA, Baird RD, Yap KC, Lam HY, Toi M, Carbone D, Geoerger B, Serra V, Jones RH, Ngeow J, Toska E, Stebbing J, Crasta K, Finn RS, Diana P, Vuina K, de Bruin RAM, Surana U, Bardia A, Kumar AP. Glaviano A, et al. Among authors: lam hy. Drug Resist Updat. 2024 Sep;76:101103. doi: 10.1016/j.drup.2024.101103. Epub 2024 Jun 25. Drug Resist Updat. 2024. PMID: 38943828 Free article. Review.
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer.
Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, Eng H, Nair MG, Makvandi P, Geoerger B, Kulke MH, Baird RD, Prabhu JS, Carbone D, Pecoraro C, Teh DBL, Sethi G, Cavalieri V, Lin KH, Javidi-Sharifi NR, Toska E, Davids MS, Brown JR, Diana P, Stebbing J, Fruman DA, Kumar AP. Glaviano A, et al. Among authors: lam hy. Mol Cancer. 2023 Aug 18;22(1):138. doi: 10.1186/s12943-023-01827-6. Mol Cancer. 2023. PMID: 37596643 Free PMC article. Review.
SHP2 inhibitors maintain TGFβ signalling through SMURF2 inhibition.
Lai X, Lui SKL, Lam HY, Adachi Y, Sim WJ, Vasilevski N, Armstrong NJ, Bridgeman SC, Main NM, Tan TZ, Tirnitz-Parker JEE, Thiery JP, Ebi H, Kumar AP, Eichhorn PJA. Lai X, et al. Among authors: lam hy. NPJ Precis Oncol. 2023 Dec 15;7(1):136. doi: 10.1038/s41698-023-00486-6. NPJ Precis Oncol. 2023. PMID: 38102334 Free PMC article.
241 results